# COVID-19 Vaccination Detoxification in LDL-C

> **NCT05839236** · PHASE1 · UNKNOWN · sponsor: **Yang I. Pachankis** · enrollment: 1 (actual)

## Conditions studied

- COVID-19 Stress Syndrome
- COVID-19 Vaccine Adverse Reaction
- COVID-19-Associated Thromboembolism
- COVID-19 Post-Intensive Care Syndrome
- COVID-19-Associated Stroke
- COVID-19 Respiratory Infection

## Interventions

- **COMBINATION_PRODUCT:** Atorvastatin Calcium Tablets

## Key facts

- **NCT ID:** NCT05839236
- **Lead sponsor:** Yang I. Pachankis
- **Sponsor class:** INDIV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-07-31
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05839236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05839236, "COVID-19 Vaccination Detoxification in LDL-C". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05839236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*